-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Reviewing SAB Biotherapeutics (NASDAQ:SABS) and Exelixis (NASDAQ:EXEL)
Reviewing SAB Biotherapeutics (NASDAQ:SABS) and Exelixis (NASDAQ:EXEL)
SAB Biotherapeutics (NASDAQ:SABS – Get Rating) and Exelixis (NASDAQ:EXEL – Get Rating) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.
Insider & Institutional Ownership
20.9% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 84.7% of Exelixis shares are held by institutional investors. 42.0% of SAB Biotherapeutics shares are held by company insiders. Comparatively, 2.9% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Get SAB Biotherapeutics alerts:Valuation and Earnings
This table compares SAB Biotherapeutics and Exelixis' gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
SAB Biotherapeutics | $60.88 million | 0.48 | -$17.15 million | N/A | N/A |
Exelixis | $1.43 billion | 3.86 | $231.06 million | $0.95 | 18.08 |
Risk & Volatility
SAB Biotherapeutics has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations and price targets for SAB Biotherapeutics and Exelixis, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
SAB Biotherapeutics | 0 | 0 | 2 | 0 | 3.00 |
Exelixis | 0 | 1 | 8 | 0 | 2.89 |
SAB Biotherapeutics presently has a consensus target price of $3.67, suggesting a potential upside of 439.69%. Exelixis has a consensus target price of $27.58, suggesting a potential upside of 60.55%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe SAB Biotherapeutics is more favorable than Exelixis.
Profitability
This table compares SAB Biotherapeutics and Exelixis' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
SAB Biotherapeutics | -68.35% | -82.05% | -46.84% |
Exelixis | 18.78% | 13.11% | 11.07% |
Summary
Exelixis beats SAB Biotherapeutics on 8 of the 12 factors compared between the two stocks.
About SAB Biotherapeutics
(Get Rating)
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
About Exelixis
(Get Rating)
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
SAB Biotherapeutics (NASDAQ:SABS – Get Rating) and Exelixis (NASDAQ:EXEL – Get Rating) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.
纳斯达克:SABS-GET评级)和Exelixis(纳斯达克:EXEL-GET评级)都是医疗公司,但哪一家更好?我们将根据这两家公司的机构持股、股息、盈利能力、收益、分析师建议、风险和估值等方面的实力进行比较。
Insider & Institutional Ownership
内部人与机构所有权
20.9% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 84.7% of Exelixis shares are held by institutional investors. 42.0% of SAB Biotherapeutics shares are held by company insiders. Comparatively, 2.9% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
SAB BioTreateutics 20.9%的股份由机构投资者持有。相比之下,Exelixis 84.7%的股份由机构投资者持有。SAB BioTreateutics 42.0%的股份由公司内部人士持有。相比之下,Exelixis 2.9%的股份由公司内部人士持有。强大的机构持股表明,对冲基金、捐赠基金和大型基金管理公司相信,一家公司有望实现长期增长。
Valuation and Earnings
估值和收益
This table compares SAB Biotherapeutics and Exelixis' gross revenue, earnings per share (EPS) and valuation.
此表比较了SAB BioTreateutics和Exelixis的毛收入、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
SAB Biotherapeutics | $60.88 million | 0.48 | -$17.15 million | N/A | N/A |
Exelixis | $1.43 billion | 3.86 | $231.06 million | $0.95 | 18.08 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
SAB生物治疗学 | 6,088万美元 | 0.48 | -1,715万美元 | 不适用 | 不适用 |
Exelixis | 14.3亿美元 | 3.86 | 2.3106亿美元 | $0.95 | 18.08 |
Risk & Volatility
风险与波动性
SAB Biotherapeutics has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.
SAB BioTreateutics的贝塔系数为1.28,表明其股价的波动性比标准普尔500指数高28%。相比之下,Exelixis的贝塔系数为0.69,这表明其股价的波动性比标准普尔500指数低31%。
Analyst Recommendations
分析师建议
This is a summary of current recommendations and price targets for SAB Biotherapeutics and Exelixis, as provided by MarketBeat.com.
这是由MarketBeat.com提供的SAB BioTreateutics和Exelixis的当前建议和价格目标的摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
SAB Biotherapeutics | 0 | 0 | 2 | 0 | 3.00 |
Exelixis | 0 | 1 | 8 | 0 | 2.89 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
SAB生物治疗学 | 0 | 0 | 2 | 0 | 3.00 |
Exelixis | 0 | 1 | 8 | 0 | 2.89 |
SAB Biotherapeutics presently has a consensus target price of $3.67, suggesting a potential upside of 439.69%. Exelixis has a consensus target price of $27.58, suggesting a potential upside of 60.55%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe SAB Biotherapeutics is more favorable than Exelixis.
SAB BioTreateutics目前的共识目标价为3.67美元,暗示潜在上涨439.69%。Exelixis的共识目标价为27.58美元,暗示潜在上涨60.55%。鉴于SAB BioTreateutics更高的共识评级和更高的可能上行空间,研究分析师显然认为SAB BioTreateutics比Exelixis更有利。
Profitability
盈利能力
This table compares SAB Biotherapeutics and Exelixis' net margins, return on equity and return on assets.
此表比较了SAB BioTreateutics和Exelixis的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
SAB Biotherapeutics | -68.35% | -82.05% | -46.84% |
Exelixis | 18.78% | 13.11% | 11.07% |
净利润率 | 股本回报率 | 资产回报率 | |
SAB生物治疗学 | -68.35% | -82.05% | -46.84% |
Exelixis | 18.78% | 13.11% | 11.07% |
Summary
摘要
Exelixis beats SAB Biotherapeutics on 8 of the 12 factors compared between the two stocks.
Exelixis在两只股票之间进行比较的12个因素中有8个超过了SAB BioTreateutics。
About SAB Biotherapeutics
关于SAB生物疗法
(Get Rating)
(获取评级)
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
SAB生物疗法公司是一家临床阶段的生物制药公司,致力于基于人类抗体的免疫疗法的开发。它应用先进的基因工程和抗体科学来开发跨染色体牛群,产生针对特定疾病的完全人类抗体,包括新冠肺炎和流感等传染病、免疫和自身免疫性疾病,如1型糖尿病、器官移植和癌症。该公司使用其DiversitAb免疫治疗平台来生产全人类多克隆抗体,而不需要人类捐赠者。它的主要候选产品包括SAB-185,这是一种治疗新冠肺炎的全人多克隆抗体候选药物,正在进行第三阶段临床试验;以及SAB-176,这是一种正在开发中的治疗或预防严重流感的全人多克隆抗体药物。该公司正在开发的针对自身免疫性疾病的临床前候选产品包括治疗1型糖尿病和器官移植诱导/排斥反应的SAB-142。该公司成立于2014年,总部设在南达科他州的苏福尔斯。
About Exelixis
关于Exelixis
(Get Rating)
(获取评级)
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Exelixis,Inc.是一家生物制药公司,致力于癌症治疗新药的开发、商业化和发现。它提供COMETRIQ、CABOMETYX、COTELLIC和MINNEBRO品牌的产品。该公司由科里·S·古德曼和斯特利奥斯·B·帕帕佐普洛斯于1994年11月15日创立,总部设在加利福尼亚州阿拉米达。
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得SAB生物疗法日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对SAB BioTreateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧